Chronic depression as a model disease for cerebral aging

Dialogues in Clinical Neuroscience

Volumn 15, Issue 1, 2013, Pages 77-85

  Bewernick, Bettina H ^a,b   Schlaepfer, Thomas E ^b  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Alzheimer's Disease; Antidepressant Therapy; Cerebral Aging; Deep Brain Stimulation; Depression; Neurodegeneration; Neuroinflammation; Neuroplasticity; Neuroprotectant; Parkinson's Disease; Plasticity

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CURCUMIN; HYDROCORTISONE; KETAMINE; NICOTINE; RESVERATROL;

AGING; ALCOHOL CONSUMPTION; ALZHEIMER DISEASE; ANTIDEPRESSANT ACTIVITY; ARTICLE; BRAIN DEPTH STIMULATION; BRAIN DYSFUNCTION; BRAIN SIZE; CELL PROLIFERATION; CEREBRAL AGING; CINGULATE GYRUS; CORPUS STRIATUM; DENTATE GYRUS; DEPRESSION; DISEASE MODEL; DOWN REGULATION; ELECTROCONVULSIVE THERAPY; GENOTOXICITY; HUMAN; HYDROCORTISONE BLOOD LEVEL; MAJOR DEPRESSION; NERVE CELL PLASTICITY; NERVE DEGENERATION; NERVOUS SYSTEM DEVELOPMENT; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NEUROTOXICITY; NEUROTRANSMISSION; NONHUMAN; NUCLEUS ACCUMBENS; OXIDATIVE STRESS; PARKINSON DISEASE; PREFRONTAL CORTEX; PSYCHOPHARMACOTHERAPY; SOCIAL STRESS; STRESS; TOBACCO DEPENDENCE;

ALZHEIMER'S DISEASE; ANTIDEPRESSANT THERAPY; CEREBRAL AGING; DEEP BRAIN STIMULATION; DEPRESSION; NEURODEGENERATION; NEUROINFLAMMATION; NEUROPLASTICITY; NEUROPROTECTANT; PARKINSON'S DISEASE; PLASTICITY;

AGING; ANIMALS; CEREBRAL CORTEX; CHRONIC DISEASE; DEEP BRAIN STIMULATION; DEPRESSION; HUMANS; NEUROGENESIS; NEURONAL PLASTICITY;

EID: 84876803435     PISSN: 12948322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (109)

1. Berton O, Nestler EJ. New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci. 2006;7:137-151.
2. Castren E. Is mood chemistry? Nat Rev Neurosci. 2005;6:241-246.
3. Hanson ND, Owens MJ, Nemeroff CB. Depression, antidepressants, and neurogenesis: a critical reappraisal. Neuropsychopharmacology. 2011;36:2589-2602.
4. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163:1905-1917.
5. Manji HK, Drevets WC, Charney DS. The cellular neurobiology of depression. Nat Med. 2001;7:541-547.
6. Cotter D, Mackay D, Landau S, Kerwin R, Everall I. Reduced glial cell density and neuronal size in the anterior cingulate cortex in major depressive disorder. Arch Gen Psychiatry. 2001;58:545-553.
7. Rajkowska G. Cell pathology in mood disorders. Semin Clin Neuropsychiatry. 2002;7:281-292.
8. Rosso IM. Review: hippocampal volume is reduced in people with unipolar depression. Evid Based Ment Health. 2005;8:45.
9. Rosso IM, Cintron CM, Steingard RJ, Renshaw PF, Young AD, Yurgelun-Todd DA. Amygdala and hippocampus volumes in pediatric major depression. Biol Psychiatry. 2005;57:21-26.
10. Manaye KF, Lei DL, Tizabi Y, Davila-Garcia MI, Mouton PR, Kelly PH. Selective neuron loss in the paraventricular nucleus of hypothalamus in patients suffering from major depression and bipolar disorder. J Neuropathol Exp Neurol. 2005;64:224-229.
11. Lavretsky H, Zheng L, Weiner MW, et al. The MRI brain correlates of depressed mood, anhedonia, apathy, and anergia in older adults with and without cognitive impairment or dementia. Int J Geriatr Psychiatry. 2008;23:1040-1050.
12. Czeh B, Lucassen PJ. What causes the hippocampal volume decrease in depression? Are neurogenesis, glial changes and apoptosis implicated? Eur Arch Psychiatry Clin Neurosci. 2007;257:250-260.
13. Sheline YI, Gado MH, Kraemer HC. Untreated depression and hippocampal volume loss. Am J Psychiatry. 2003;160:1516-1518.
14. Eriksson PS, Perfilieva E, Bjork-Eriksson T, et al. Neurogenesis in the adult human hippocampus. Nat Med. 1998;4:1313-1317.
15. Maes M, Yirmyia R, Noraberg J, et al. The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression. Metab Brain Dis. 2009;24:27-53.
16. Maes M. The immunoregulatory effects of antidepressants. Hum Psychopharmacol. 2001;16:95-103.
17. Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 2006;27:24-31.
18. Schiepers OJ, Wichers MC, Maes M. Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29:201-217.
19. Capuron L, Miller AH. Cytokines and psychopathology: lessons from interferon-alpha. Biol Psychiatry. 2004;56:819-824.
20. Pollak Y, Yirmiya R. Cytokine-induced changes in mood and behaviour: implications for 'depression due to a general medical condition', immunotherapy and antidepressive treatment. Int J Neuropsychopharmacol. 2002;5:389-399.
21. Rasgon NL, Kenna HA. Insulin resistance in depressive disorders and Alzheimer's disease: revisiting the missing link hypothesis. Neurobiol Aging. 2005;26(suppl 1):103-107.
22. Wolkowitz OM, Reus VI, Mellon SH. Of sound mind and body: depression, disease, and accelerated aging. Dialogues Clin Neurosci. 2011;13:25-39.
23. Joseph JA, Shukitt-Hale B, Casadesus G, Fisher D. Oxidative stress and inflammation in brain aging: nutritional considerations. Neurochem Res. 2005;30:927-935.
24. Cumurcu BE, Ozyurt H, Etikan I, Demir S, Karlidag R. Total antioxidant capacity and total oxidant status in patients with major depression: impact of antidepressant treatment. Psychiatry Clin Neurosci. 2009;63:639-645.
25. Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. Biol Psychiatry. 2006;59:1116-1127.
26. Groves JO. Is it time to reassess the BDNF hypothesis of depression? Mol Psychiatry. 2007;12:1079-1088.
27. Hartmann N, Boehner M, Groenen F, Kalb R. Telomere length of patients with major depression is shortened but independent from therapy and severity of the disease. Depress Anxiety. 2010;27:1111-1116.
28. Choi J, Fauce SR, Effros RB. Reduced telomerase activity in human T lymphocytes exposed to cortisol. Brain Behav Immun. 2008;22:600-605.
29. D'Sa C, Duman RS. Antidepressants and neuroplasticity. Bipolar Disord. 2002;4:183-194.
30. Magarinos AM, McEwen BS, Flugge G, Fuchs E. Chronic psychosocial stress causes apical dendritic atrophy of hippocampal CA3 pyramidal neurons in subordinate tree shrews. J Neurosci. 1996;16:3534-3540.
31. McEwen BS. Stress and hippocampal plasticity. Annu Rev Neurosci. 1999;22:105-122.
32. Malberg JE, Eisch AJ, Nestler EJ, Duman RS. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci. 2000;20:9104-9110.
33. Santarelli L, Saxe M, Gross C, et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science. 2003;301:805-809.
34. Zunszain PA, Hepgul N, Pariante CM. Inflammation and depression. Curr Topics Behav Neurosci. In press.
35. Parrott AC. Cigarette-derived nicotine is not a medicine. World J Biol Psychiatry. 2003;4:49-55.
36. Steuber TL, Danner F. Adolescent smoking and depression: which comes first? Addict Behav. 2006;31:133-136.
37. Edward SJ, Stevens AJ, Braunholtz DA, Lilford RJ, Swift T. The ethics of placebo-controlled trials: a comparison of inert and active placebo controls. World J Surg. 2005;29:610-614.
38. Glassman AH, Covey LS, Stetner F, Rivelli S. Smoking cessation and the course of major depression: a follow-up study. Lancet. 16 2001;357:1929-1932.
39. Cook JW, Spring B, McChargue D. Influence of nicotine on positive affect in anhedonic smokers. Psychopharmacology (Berl). 2007;192:87-95.
40. McClernon FJ, Hiott FB, Westman EC, Rose JE, Levin ED. Transdermal nicotine attenuates depression symptoms in nonsmokers: a double-blind, placebo-controlled trial. Psychopharmacology (Berl). 2006;189:125-133.
41. Copeland RL, Jr, Das JR, Kanaan YM, Taylor RE, Tizabi Y. Antiapoptotic effects of nicotine in its protection against salsolinol-induced cytotoxicity. Neurotoxicity Res. 2007;12:61-69.
42. Copeland RL, Jr, Leggett YA, Kanaan YM, Taylor RE, Tizabi Y. Neuroprotective effects of nicotine against salsolinol-induced cytotoxicity: implications for Parkinson's disease. Neurotoxicity Res. 2005;8:289-293.
43. Ross GW, Petrovitch H. Current evidence for neuroprotective effects of nicotine and caffeine against Parkinson's disease. Drugs Aging. 2001;18:797-806.
44. Thacker EL, O'Reilly EJ, Weisskopf MG, et al. Temporal relationship between cigarette smoking and risk of Parkinson disease. Neurology. 2007;68:764-768.
45. Baron JA. Beneficial effects of nicotine and cigarette smoking: the real, the possible and the spurious. Br Med Bull. 1996;52:58-73.
46. Cui WY, Li MD. Nicotinic modulation of innate immune pathways via alpha7 nicotinic acetylcholine receptor. J NeuroImmune Pharmacol. 2010;5:479-488.
47. Piao WH, Campagnolo D, Dayao C, Lukas RJ, Wu J, Shi FD. Nicotine and inflammatory neurological disorders. Acta pharmacologica Sinica. 2009;30:715-722.
48. Shi FD, Piao WH, Kuo YP, Campagnolo DI, Vollmer TL, Lukas RJ. Nicotinic attenuation of central nervous system inflammation and autoimmunity. J Immunol. 2009;182:1730-1739.
49. Getachew B, Hauser SR, Taylor RE, Tizabi Y. Alcohol-induced depressivelike behavior is associated with cortical norepinephrine reduction. Pharmacol Biochem Behav. 2010;96:395-401.
50. Hauser SR, Ding ZM, Getachew B, et al. The posterior ventral tegmental area mediates alcohol-seeking behavior in alcohol-preferring rats. J Pharmacol Exp Ther. 2011;336:857-865.
51. Collins MA, Neafsey EJ, Mukamal KJ, et al. Alcohol in moderation, cardioprotection, and neuroprotection: epidemiological considerations and mechanistic studies. Alcohol Clin Exp Res. 2009;33:206-219.
52. Belmadani A, Zou JY, Schipma MJ, Neafsey EJ, Collins MA. Ethanol preexposure suppresses HIV-1 glycoprotein 120-induced neuronal degeneration by abrogating endogenous glutamate/Ca2+-mediated neurotoxicity. Neuroscience. 2001;104:769-781.
53. Park HJ, Lee PH, Ahn YW, et al. Neuroprotective effect of nicotine on dopaminergic neurons by anti-inflammatory action. Eur J Neurosci. 2007;26:79-89.
54. Xu Y, Wang Z, You W, et al. Antidepressant-like effect of trans-resveratrol: involvement of serotonin and noradrenaline system. Eur Neuropsychopharmacol. 2010;20:405-413.
55. Chen LW, Wang YQ, Wei LC, Shi M, Chan YS. Chinese herbs and herbal extracts for neuroprotection of dopaminergic neurons and potential therapeutic treatment of Parkinson's disease. CNS Neurol Disord Drug Targets. 2007;6:273-281.
56. Tredici G, Miloso M, Nicolini G, Galbiati S, Cavaletti G, Bertelli A. Resveratrol, map kinases and neuronal cells: might wine be a neuroprotectant? Drugs Exp Clin Res. 1999;25:99-103.
57. Vingtdeux V, Dreses-Werringloer U, Zhao H, Davies P, Marambaud P. Therapeutic potential of resveratrol in Alzheimer's disease. BMC Neurosci. 2008;9(suppl 2):S6.
58. Zhang F, Wang H, Wu Q, et al. Resveratrol protects cortical neurons against microglia-mediated neuroinflammation. Phytother Res. In press.
59. Aggarwal BB, Harikumar KB. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int J Biochem Cell Biol. 2009;41:40-59.
60. Jurenka JS. Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: a review of preclinical and clinical research. Alt Med Rev. 2009;14:141-153.
61. Bhutani MK, Bishnoi M, Kulkarni SK. Anti-depressant like effect of curcumin and its combination with piperine in unpredictable chronic stressinduced behavioral, biochemical and neurochemical changes. Pharmacol Biochem Behav. 2009;92:39-43.
62. Kulkarni SK, Bhutani MK, Bishnoi M. Antidepressant activity of curcumin: involvement of serotonin and dopamine system. Psychopharmacology (Berl). 2008;201:435-442.
63. Darvesh AS, Carroll RT, Bishayee A, Novotny NA, Geldenhuys WJ, Van der Schyf CJ. Curcumin and neurodegenerative diseases: a perspective. Expert Opin Investig Drugs. 2012;21:1123-1140.
64. Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47:351-354.
65. Zarate CA, Jr., Singh JB, Carlson PJ, et al. A randomized trial of an Nmethyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63:856-864.
66. Maeng S, Zarate CA, Jr, Du J, et al. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry. 2008;63:349-352.
67. Mayberg HS. Limbic-cortical dysregulation: a proposed model of depression. J Neuropsychiatry Clin Neurosci. 1997;9:471-481.
68. Greenberg BD, Gabriels LA, Malone DA, Jr, et al. Deep brain stimulation of the ventral internal capsule/ventral striatum for obsessive-compulsive disorder: worldwide experience. Mol Psychiatry. 2010;15:64-79.
69. Malone DA, Jr, Dougherty DD, Rezai AR, et al. Deep brain stimulation of the ventral capsule/ventral striatum for treatment-resistant depression. Biol Psychiatry. 2009;65:267-275.
70. Schlaepfer T, Lieb K. Deep brain stimulation for treatment refractory depression. Lancet. 2005;366:1420-1422.
71. Bewernick BH, Hurlemann R, Matusch A, et al. Nucleus accumbens deep brain stimulation decreases ratings of depression and anxiety in treatmentresistant depression. Biol Psychiatry. 2010;67:110-116.
72. Bewernick BH, Kayser S, Sturm V, Schlaepfer TE. Long-term effects of nucleus accumbens deep brain stimulation in treatment-resistant depression: evidence for sustained efficacy. Neuropsychopharmacology. 2012;37:1975-1985.
73. Holtzheimer PE, Kelley ME, Gross RE, et al. Subcallosal cingulate deep brain stimulation for treatment-resistant unipolar and bipolar depression. Arch Gen Psychiatry. 2012;69:150-158.
74. Kennedy SH, Giacobbe P, Rizvi SJ, et al. Deep brain stimulation for treatment-resistant depression: follow-up after 3 to 6 years. Am J Psychiatry. 2011;168:502-510.
75. Lozano AM, Giacobbe P, Hamani C, et al. A multicenter pilot study of subcallosal cingulate area deep brain stimulation for treatment-resistant depression. J Neurosurg. 2012;116:315-322.
76. Puigdemont D, Perez-Egea R, Portella MJ, et al. Deep brain stimulation of the subcallosal cingulate gyrus: further evidence in treatment-resistant major depression. Int J Neuropsychopharmacol. 2011:1-13.
77. Coenen VA, Panksepp J, Hurwitz TA, Urbach H, Madler B. Human medial forebrain bundle (MFB) and anterior thalamic radiation (ATR): imaging of two major subcortical pathways and the dynamic balance of opposite affects in understanding depression. J Neuropsychiatry Clin Neurosci. 2012;24: 223-236
78. Coenen VA. Schlaepfer TE, Maedler B, Panksepp J. Cross-species affective functions of the medial forebrain bundle-implications for the treatment of affective pain and depression in humans. Neurosci Biobehav Rev. 2011;35:1971-1981.
79. Coenen, VA, Schlaepfer TE, Maedler B, Panksepp J. Cross-species affective functions of the medial forebrain bundle-Implications for the treatment of affective pain and depression in humans. Neurosci Biobehav Rev. 2011;35 1971-1981
80. Schlaepfer T, Bewernick B, Kayser S, Mädler B, Coenen VA. Rapid effects of deep brain stimulation for treatment resistant major depression. Biol Psychiatry. In press.
81. Deniau JM, Degos B, Bosch C, Maurice N. Deep brain stimulation mechanisms: beyond the concept of local functional inhibition. Eur J Neurosci. 2010;32:1080-1091.
82. McIntyre CC, Savasta M, Goff LKL, Vitek JL. Uncovering the mechanism(s) of action of deep brain stimulation: activation, inhibition, or both. Clin Neurophysiol. 2004;115:1239-1248.
83. Encinas JM, Hamani C, Lozano AM, Enikolopov G. Neurogenic hippocampal targets of deep brain stimulation. J Comp Neurol. 2011;519:6-20. 84. Toda H, Hamani C, Fawcett AP, Hutchison WD, Lozano AM. The regulation of adult rodent hippocampal neurogenesis by deep brain stimulation. J Neurosurg. 2008;108:132-138.
84. Toda H, Hamani C, Fawcett AP, Hutchison WD, Lozano AM. The regulation of adult rodent hippocampal neurogenesis by deep brain stimulation. J Neurosurg. 2008;108:132-138.
85. Stone SS, Teixeira CM, Devito LM, et al. Stimulation of entorhinal cortex promotes adult neurogenesis and facilitates spatial memory. J Neurosci. 2011;31:13469-13484.
86. Khaindrava V, Salin P, Melon C, Ugrumov M, Goff LKL, Daszuta A. High frequency stimulation of the subthalamic nucleus impacts adult neurogenesis in a rat model of Parkinson's disease. Neurobiol Dis. 2011;42:284-291.
87. Gubellini P, Eusebio A, Oueslati A, Melon C, Goff LKL, Salin P. Chronic high-frequency stimulation of the subthalamic nucleus and LDOPA treatment in experimental parkinsonism: effects on motor behaviour and striatal glutamate transmission. Eur J Neurosci. 2006;24:1802-1814.
88. Harnack D, Meissner W, Jira JA, Winter C, Morgenstern R, Kupsch A. Placebo-controlled chronic high-frequency stimulation of the subthalamic nucleus preserves dopaminergic nigral neurons in a rat model of progressive Parkinsonism. Exp Neurol. 2008;210:257-260.
89. Maesawa S, Kaneoke Y, Kajita Y, et al. Long-term stimulation of the subthalamic nucleus in hemiparkinsonian rats: neuroprotection of dopaminergic neurons. J Neurosurg. 2004;100:679-687.
90. Temel Y, Visser-Vandewalle V, Kaplan S, et al. Protection of nigral cell death by bilateral subthalamic nucleus stimulation. Brain Res. 2006;1120:100-105.
91. Wallace BA, Ashkan K, Heise CE, et al. Survival of midbrain dopaminergic cells after lesion or deep brain stimulation of the subthalamic nucleus in MPTP-treated monkeys. Brain. 2007;130:2129-2145.
92. Spieles-Engemann AL, Collier TJ, Sortwell CE. A functionally relevant and long-term model of deep brain stimulation of the rat subthalamic nucleus: advantages and considerations. Eur J Neurosci. 2010;32:1092-1099.
93. Krishnan V, Nestler EJ. The molecular neurobiology of depression. Nature. 16 2008;455:894-902.
94. Insel TR. Faulty circuits. Scientific American. 2010;302:44-51.
95. Atri A. Effective pharmacological management of Alzheimer's disease. Am J Managed Care. 2011;17(suppl 13):S346-355.
96. Bartus RT, Dean RL, 3rd, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science. 1982;217:408-414.
97. Dumas JA, Newhouse PA. The cholinergic hypothesis of cognitive aging revisited again: cholinergic functional compensation. Pharmacol Biochem Behav. 2011;99:254-261.
98. Hansen RA, Gartlehner G, Webb AP, Morgan LC, Moore CG, Jonas DE. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. Clin Interv Aging. 2008;3:211-225.
99. Dumas JA, Newhouse PA. The cholinergic hypothesis of cognitive aging revisited again: cholinergic functional compensation. Pharmacol Biochem Behav. 2011;99:943-951.
100. Nelson PT, Head E, Schmitt FA, et al. Alzheimer's disease is not "brain aging": neuropathological, genetic, and epidemiological human studies. Acta Neuropathologica. 2011;121:571-587.
101. Gleichmann M, Mattson MP. Alzheimer's disease and neuronal network activity. Neuromol Med. 2010;12:44-47.
102. Sperling RA, Dickerson BC, Pihlajamaki M, et al. Functional alterations in memory networks in early Alzheimer's disease. Neuromol Med. 2010;12:27-43.
103. Laxton AW, Tang-Wai DF, McAndrews MP, et al. A phase I trial of deep brain stimulation of memory circuits in Alzheimer's disease. Ann Neurol. 2010;68:521-534.
104. De Souza MB, De Lemos RR, Da Cunha JE, Filho JLDL, De Oliveira JR. Searching for new genetic risk factors for neuropsychiatric disorders in expression databases. J Mol Neurosci. 2010;41:193-197.
105. Leonard BE. Inflammation, depression and dementia: are they connected? Neurochem Res. 2007;32:1749-1756.
106. Leonard BE, Myint A. The psychoneuroimmunology of depression. Hum Psychopharmacol. 2009;24:165-175.
107. Krabbe KS, Mortensen EL, Avlund K, et al. Brain-derived neurotrophic factor predicts mortality risk in older women. J Am Geriatr Soc. 2009;57:1447-1452.
108. Wilson CJ, Finch CE, Cohen HJ. Cytokines and cognition--the case for a head-to-toe inflammatory paradigm. J Am Geriatr Soc. 2002;50:2041-2056.
109. Hurley LL, Tizabi Y. Neuroinflammation, neurodegeneration, and depression. Neurotoxicity Res. 2013;23:131-144.